publication date: Jun. 5, 2015

ESMO Scale Stratifies Magnitude of Clinical Benefit of Cancer Drugs


The European Society for Medical Oncology May 30 published the ESMO Magnitude of Clinical Benefit Scale, a tool to assist oncology clinicians in evaluating the most effective anti-cancer medicines for their patients.

According to the society, the ESMO-MCBS offers a “rational, structured and consistent approach to stratify a drug’s clinically meaningful benefit”—a scale that can be used in public policy decision-making, to develop or improve clinical guidelines, in day-to-day clinical situations.

A manuscript describing the project and reporting the main results from a field testing of the scale conducted on 77 cancer medicines across 10 cancer types was published May 30 in Annals of Oncology.

“While it is known that the value of any new treatment is determined by the magnitude of its clinical benefit against its cost, to date there has not been a standard tool for grading such magnitude,” says Nathan Cherny, director of the Cancer Pain and Palliative Medicine Service, Department of Medical Oncology, Shaare Zedek Medical Center in Israel, who formulated the idea some years ago.

The ESMO-MCBS project was presented at the American Society of Clinical Oncology annual meeting in Chicago in an ASCO/ESMO joint session, called “Global Perspective on Value.”

The session demonstrated how the scale could provide useful information when used in conjunction with the preliminary results of the European snapshot perception survey on anti-cancer medicine availability conducted last year.

“As the international organization committed to the … Continue reading 41-22 ESMO Scale Stratifies Magnitude of Clinical Benefit of Cancer Drugs

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.